1h
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzdâ„¢ Clinical Trial Published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results